BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 14, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/11 cls
Anadys Pharmaceuticals Inc. (NASDAQ:ANDS) JMP Securities Liisa Bayko Downgrade Market perform (from market outperform) 2% $2.39
Bayko thinks Anadys will need to partner ANA598 for further development, but believes the biotech will have a hard time finding an attractive deal. She said the HCV field is quickly turning to early exploration of multiple agents in combination and believes ANA598 would "likely not hold ground on a single-agent basis." The oral non-nucleoside NS5B polymerase inhibitor is in Phase II testing.
Basilea Pharmaceutica AG (SIX:BSLN) UBS Guillaume van Renterghem Upgrade Buy (from neutral) 3% CHF72
van Renterghem said the pipeline is undervalued. He thinks the stock does not account for upcoming newsflow, including Phase III data for Toctino alitretinoin to treat severe chronic hand eczema anticipated next half....

Read the full 914 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >